Atai Life Sciences N.V. (NASDAQ:ATAI) marked $3.44 per share on Wednesday, down from a previous closing price of $3.67. While Atai Life Sciences N.V. has underperformed by -6.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATAI fell by -78.57%, with highs and lows ranging from $17.81 to $2.95, whereas the simple moving average fell by -32.08% in the last 200 days.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
On November 30, 2021, Maxim Group started tracking Atai Life Sciences N.V. (NASDAQ: ATAI) recommending Buy. A report published by ROTH Capital on November 11, 2021, Initiated its previous ‘Buy’ rating for ATAI. H.C. Wainwright also rated ATAI shares as ‘Buy’, setting a target price of $40 on the company’s shares in an initiating report dated October 18, 2021. Jefferies Initiated an Buy rating on September 01, 2021, and assigned a price target of $27. RBC Capital Mkts initiated its ‘Sector Perform’ rating for ATAI, as published in its report on July 13, 2021. Credit Suisse’s report from July 13, 2021 suggests a price prediction of $25 for ATAI shares, giving the stock a ‘Outperform’ rating. Cowen also rated the stock as ‘Outperform’.
Analysis of Atai Life Sciences N.V. (ATAI)
In order to gain a clear picture of Atai Life Sciences N.V.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -52.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 14.70, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 767.53K can be a very valuable indicator of volatility for ATAI stock. On a monthly basis, the volatility of the stock is set at 6.28%, whereas on a weekly basis, it is put at 6.79%, with a loss of -14.00% over the past seven days. Furthermore, long-term investors anticipate a median target price of $23.96, showing growth from the present price of $3.44, which can serve as yet another indication of whether ATAI is worth investing in or should be passed over.
How Do You Analyze Atai Life Sciences N.V. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 9.35%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 32.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ATAI shares?
The recent increase in stakes in ATAI appears to be a result of several institutional investors and hedge funds increasing their positions. ARK Investment Management LLC made another decreased to its shares in ATAI during the first quarter, downing its stake by -3.40%. During the last quarter, the company picked up -56,912 additional shares for a total stake of worth $7.29 million, bringing number of shares owned by the company to 1,619,035.
ATAI shares are owned by institutional investors to the tune of 32.30% at present.